GHK vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
GHKAnti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- GHK is the natural tripeptide (Gly-His-Lys) released from human albumin that activates tissue remodeling, collagen synthesis, and anti-aging gene expression. The copper-free form is the biological signaling molecule; it chelates copper in tissue to form GHK-Cu but also has independent biological activity.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- Extremely short as free peptide; tissue binding extends local effects
- ~2–5 hours
- Admin Route
- SubQ, Topical, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 100–500 mcg
- 5–10 mg
- Frequency
- Daily or 5x per week
- Daily to several times per week
- Key Benefits
- Stimulates collagen and extracellular matrix synthesis
- Activates tissue repair gene expression programs
- Anti-aging: reverses 57% of age-related gene changes
- Antioxidant and anti-inflammatory
- Wound healing and skin barrier repair
- Improves skin laxity, texture, and radiance
- Neuroprotective (stimulates NGF, BDNF)
- Anti-fibrotic in liver and lung models
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Excellent safety profile (naturally occurring peptide)
- Rare: mild injection site reaction (SC)
- No significant adverse effects identified in research
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —